IXICO announces two new biopharmaceutical contracts

 Providing specialist imaging clinical trials services for rare neurological diseases

 IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces that it has signed contracts with two biopharmaceutical companies to provide its technology-enabled imaging services to support an early phase study in Huntington’s Disease (HD) and a phase 3 study in another rare neurological disease. The contracts are both the first to be signed with these clients.  

As the selected imaging analysis partner for these studies, IXICO will utilise its data analytics expertise, developed over many years of working in the field, to provide critical insights which will support the evaluation of drug safety and efficacy. Study planning and site set-up activities are due to start imminently, contributing revenues for 2019 and into future periods.

The HD contract has a total value of approximately £2.0 million, which will be delivered over a seven-year term. HD is a rare genetic neurodegenerative disorder that affects movement, cognition and behaviour. This is an area of significant unmet medical need as there are currently no effective marketed treatments.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...